Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$65.43 USD

65.43
204,793

+1.50 (2.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $65.50 +0.07 (0.11%) 7:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Zacks Equity Research

ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 207.14% and 14.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks Equity Research

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why it is Prudent for Investors to Hold Humana Stock for Now

by Zacks Equity Research

HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.

Zacks Equity Research

Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About ANI (ANIP) Rating Upgrade to Buy

by Zacks Equity Research

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Medical Stocks Lagging Adagene (ADAG) This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks Equity Research

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why Retaining Cigna Stock is a Smart Move for Investors Now

by Zacks Equity Research

CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.

Zacks Equity Research

Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Compelling Reasons to Hold on to Ensign Group Stock Now

by Zacks Equity Research

ENSG drives revenue growth through advanced healthcare services, strategic acquisitions, and rental income from triple-net leases, supported by strong cash reserves and a 21-year dividend growth streak.

Zacks Equity Research

ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks Equity Research

Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma

by Zacks Equity Research

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.

Zacks Equity Research

AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe

by Zacks Equity Research

The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.

Zacks Equity Research

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.